Opus Point Partners Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Opus Point Partners Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-44,500	Closed	-$891K	–	47
2018 Q3	$891K	Buy	44,500 +29,500	+197%	+$693K	2.13%	20
2018 Q2	$387K	Hold	15,000	–	–	0.84%	31
2018 Q1	$359K	Sell	15,000 -15,000	-50%	-$473K	0.7%	33
2017 Q4	$1.02M	Hold	30,000	–	–	0.88%	34
2017 Q3	$635K	Hold	30,000	–	–	0.57%	40
2017 Q2	$525K	Sell	30,000 -30,000	-50%	-$496K	0.48%	47
2017 Q1	$1.05M	Hold	60,000	–	–	0.78%	34
2016 Q4	$1.01M	Hold	60,000	–	–	0.81%	33
2016 Q3	$985K	Buy	60,000 +14,802	+33%	+$225K	0.55%	32
2016 Q2	$684K	Sell	45,198 -8,802	-16%	-$145K	0.66%	30
2016 Q1	$781K	Sell	54,000 -26,000	-33%	-$438K	0.6%	36
2015 Q4	$2.27M	Buy	+80,000	New	+$1.35M	1.5%	22

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Opus Point Partners Management's ADMS Position: Q4 2018 in Review

Opus Point Partners Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 44,500 shares — an estimated $891K sold.

Opus Point Partners Management first reported a position in ADMS in Q4 2015 and held it in 12 quarters. The position peaked at $2.27M in Q4 2015. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Opus Point Partners Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opus Point Partners Management sold 44,500 Adamas Pharmaceuticals shares in Q4 2018, an estimated $891K.
Opus Point Partners Management first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 12 quarters.
Opus Point Partners Management's Adamas Pharmaceuticals position peaked at $2.27M in Q4 2015.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.